Could Verastem, Inc. (VSTM) Gain Strenght After Forming Bearish H&S?

January 2, 2018 - By Winifred Garcia

Investors sentiment increased to 1.4 in 2017 Q3. Its up 0.23, from 1.17 in 2017Q2. It improved, as 6 investors sold Verastem, Inc. shares while 19 reduced holdings. 19 funds opened positions while 16 raised stakes. 12.96 million shares or 49.25% more from 8.68 million shares in 2017Q2 were reported.
Tower Cap Limited Liability Corp (Trc) holds 579 shares or 0% of its portfolio. Moreover, Northern Trust Corporation has 0% invested in Verastem, Inc. (NASDAQ:VSTM) for 66,519 shares. Moreover, Virtu Fin Ltd Liability Corp has 0% invested in Verastem, Inc. (NASDAQ:VSTM). Moreover, Beaumont Ltd Com has 0.01% invested in Verastem, Inc. (NASDAQ:VSTM). Wells Fargo And Mn owns 19,951 shares or 0% of their US portfolio. Creative Planning reported 0% in Verastem, Inc. (NASDAQ:VSTM). Highbridge Cap Ltd Limited Liability Company has 0.01% invested in Verastem, Inc. (NASDAQ:VSTM). 5,011 are owned by Bancorp Of America De. Jacobs Levy Equity Mngmt stated it has 160,390 shares. Acadian Asset Limited Liability Corp stated it has 42,410 shares. The Florida-based Raymond James Fin Serv has invested 0% in Verastem, Inc. (NASDAQ:VSTM). Invesco Ltd owns 72,656 shares for 0% of their portfolio. Blackrock Inc reported 967,593 shares. Art Lc has invested 0.05% in Verastem, Inc. (NASDAQ:VSTM). Citadel Advsrs Limited Liability Corp stated it has 41,662 shares or 0% of all its holdings.

The stock of Verastem, Inc. (VSTM) formed H&S with $2.98 target or 3.00 % below today’s $3.07 share price. The 8 months Head & Shoulders indicates high risk for the $155.15M company. It was reported on Jan, 2 by If the $2.98 price target is reached, the company will be worth $4.65 million less.
Head-and-shoulders are one of the best chart patterns to trade. They work in bear and bull markets and according to many researchers have very low failure rate. Even thought they have high pullback rate, such patters usually provide good risk-reward entry opportunities. The percentage of stocks meeting price targets is 55%.

The stock decreased 2.85% or $0.09 during the last trading session, reaching $3.07. About 1.12 million shares traded or 33.76% up from the average. Verastem, Inc. (NASDAQ:VSTM) has risen 71.53% since January 2, 2017 and is uptrending. It has outperformed by 54.83% the S&P500.

Analysts await Verastem, Inc. (NASDAQ:VSTM) to report earnings on March, 22. They expect $-0.43 earnings per share, down 34.38 % or $0.11 from last year’s $-0.32 per share. After $-0.61 actual earnings per share reported by Verastem, Inc. for the previous quarter, Wall Street now forecasts -29.51 % EPS growth.

Verastem, Inc. (NASDAQ:VSTM) Ratings Coverage

Among 10 analysts covering Verastem (NASDAQ:VSTM), 5 have Buy rating, 0 Sell and 5 Hold. Therefore 50% are positive. Verastem has $17 highest and $1.5000 lowest target. $8.31’s average target is 170.68% above currents $3.07 stock price. Verastem had 29 analyst reports since September 9, 2015 according to SRatingsIntel. As per Thursday, September 17, the company rating was maintained by H.C. Wainwright. H.C. Wainwright maintained it with “Buy” rating and $6.50 target in Friday, March 24 report. The stock has “Buy” rating by Oppenheimer on Tuesday, August 8. Raymond James downgraded Verastem, Inc. (NASDAQ:VSTM) on Tuesday, September 29 to “Outperform” rating. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, December 13. The firm has “Buy” rating given on Monday, September 25 by Cantor Fitzgerald. The stock of Verastem, Inc. (NASDAQ:VSTM) has “Neutral” rating given on Monday, September 28 by Roth Capital. Oppenheimer maintained Verastem, Inc. (NASDAQ:VSTM) rating on Friday, June 16. Oppenheimer has “Buy” rating and $600 target. Cantor Fitzgerald downgraded the shares of VSTM in report on Tuesday, September 29 to “Hold” rating. The company was maintained on Monday, June 26 by Oppenheimer.

More important recent Verastem, Inc. (NASDAQ:VSTM) news were published by: which released: “Verastem: Looks Undervalued Despite Cash Concerns” on December 28, 2017, also published article titled: “Verastem: Too Cheap”, published: “Verastem Announces Clinical Data from the Pivotal Phase 3 DUOâ„¢ Study …” on December 10, 2017. More interesting news about Verastem, Inc. (NASDAQ:VSTM) was released by: and their article: “Verastem: Revisiting This Small Biotech Name After ASH” with publication date: December 13, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.